Dear Sir,I appreciate comments from the authors.[1] I am glad that article on ziv-aflibercept has attracted attention from readers for Indian Journal of Ophthalmology. I agree with the authors that we do not have long-term data on ziv-aflibercept; therefore, I reported short-term safety results. After observing no clinical side effects in injected eye on the 5th day, I injected in the other eye. The patient was stable during the treatment-free interval with visual acuity of 20/100 before the recurrent attack. The response to ziv-aflibercept was better than bevacizumab. Therefore, ziv-aflibercept was considered as the treatment of choice at 1-month follow-up as well. The patient is under regular treatment until now. Therefore, I am unable to comment upon whether ziv-aflibercept prolonged the treatment-free interval or not.Again, I appreciate authors’ interest in this article.